PLATELET BIOGENESIS, INC
Millifluidic bioreactor system for clinical-scale production of donor-independent platelets from human induced pluripotent stem cells (hiPSCs)
- Sector
- Biotech
- Headquarters
- Chestnut Hill, MA
- Founded
- 2014
- Latest Form D
- $35.4M, Nov 2021
- Total capital
- $66.5M
- Federal grants
- $3.6M
- 3 awards · 2016–2020
- Rank in peer group#9 of 18
- Private capital raised
- $57.9M
- 4 Form D · last Nov 2021
- 60 months since last filing
- Federal contracts
- $5M
- 1 award · Health and Human S
- Rank in Biotech#79 of 4373
- Granted patents
- 0
- 26 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$35.4M
- Federal grantHealth and Human S · Phase II · PLT+ Characterization and IND-Enabling Studies$3M
- Federal contractHealth and Human S · Utilizing The Contractors Technology, Human Induced Pluripotent Stem Cells Will Undergo Differentiation To Pre-megakaryocytes (premk+), Which Are Stockpiled Through Cryopreservation. Frozen Premk+ Are Thawed And Further Differentiated To Mature Megak$5M
- Private capital raisedForm D · SEC · 3rd filing$11.4M
- Private capital raisedForm D · SEC · 2nd filing$10M
- Federal grantHealth and Human S · Phase I · Platelet Bioreactor for Treatment of Radiation-Induced Thrombocytopenia$600K
- Federal grantHealth and Human S · Phase I · Development of an intellectual property (IP) strategy for the commercial advancement of a Direct Phase II SBIR-funded human platelet bioreactor$50K
- Private capital raisedForm D · SEC · 1st filing$1.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 18 peers
Line = medianBiotech · Device
- Federal grants#9 · top 50%
- Linked publications#4 · top 22%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Sven Erik KarlssonResearcherExecutive OfficerLinked by $50K in grants as PI
- Chidozie UgwumbaDirectorNamed in SEC Form D filings
- Jonathan ThonDirector, Executive OfficerNamed in SEC Form D filings
- Joseph ItalianoDirectorNamed in SEC Form D filings
- Mark McDadeDirectorNamed in SEC Form D filings
- Peter Erik FinnExecutive OfficerNamed in SEC Form D filings
Show all 11 people
- Philip ReillyDirectorNamed in SEC Form D filings
- Richard MurrayDirectorNamed in SEC Form D filings
- Sam RastyExecutive Officer, DirectorNamed in SEC Form D filings
- Steve AltschulerDirectorNamed in SEC Form D filings
- Steven AltschulerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 26- PendingImproved Methods And Production Of Novel PlateletsUSPTOApplication PCTUS2021032646
- PendingNovel Anucleated Cells As Source For Treatment Of Platelet Rich Plasma Dependent DisordersUSPTOApplication PCTUS2021032353
- PendingNovel Anucleated Cells For The Treatment Of DiseasesUSPTOApplication PCTUS2021024442
Show all 26 patent records
- Improved Methods And Production Of Novel PlateletsApplication PCTUS2021032646Pending
- Novel Anucleated Cells As Source For Treatment Of Platelet Rich Plasma Dependent DisordersApplication PCTUS2021032353Pending
- Novel Anucleated Cells For The Treatment Of DiseasesApplication PCTUS2021024442Pending
- Novel Anucleated Cells And Uses ThereofApplication PCTUS2021024359Pending
- Systems And Methods For Forming A Fluidic SystemApplication PCTUS2021019660Pending
- Novel Anucleated Cells As Source For Platelet Rich Plasma And Uses ThereofApplication 63144033Pending
- Novel Anucleated Cells For The Treatment Of DiseasesApplication 63142586Pending
- Novel Anucleated Cells For Drug Delivery And Methods Of Use ThereofApplication PCTUS2020067324Pending
- Novel Anucleated Cells For The Treatment Of DiseasesApplication 63125490Pending
- Novel Anucleated Cells As Source For Platelet Rich Plasma And Uses ThereofApplication 63106009Pending
- Anucleated Cells And Uses ThereofApplication 63105693Pending
- Anucleated Cells For Treating Autoimmune DisordersApplication 63104871Pending
- Production Of Novel PlateletsApplication 63025209Pending
- Pathogen Neutralization With Anucleated CellsApplication 63024649Pending
- Novel Anucleated Cells As Source For Platelet Rich Plasma And Uses ThereofApplication 63024587Pending
- Novel Anucleated Cells For Treating Autoimmune DisordersApplication 63000866Pending
- Novel Anucleated Cells And Uses ThereofApplication 63000848Pending
- Systems And Methods For Forming A Fluidic SystemApplication 62981373Pending
- Stacked Recirculating BioreactorApplication PCTUS2019042671Pending
- Compositions For Drug Delivery And Methods Of Use ThereofApplication PCTUS2019040021Pending
- Compositions And Methods For Producing MegakaryocytesApplication PCTUS2019012437Pending
- Stacked Recirculating BioreactorApplication 62700495Pending
- Compositions For Drug Delivery And Methods Of Use ThereofApplication 62692277Pending
- Recirculating BioreactorApplication PCTUS2018021354Pending
- Compositions And Methods For Producing MegakaryocytesApplication 62614117Pending
- Recirculating BioreactorApplication 62468008Pending
Recent research by its founders
- A Novel Allogeneic Cell Therapy That Targets Pathogenic Autoantibodies for the Treatment of Immune Thrombocytopenia20211 cites
- Engineering and manufacturing of probiotic E. Coli to treat metabolic disorder20190 cites
- Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria2018582 cites
Related companies, and why
- Shuttle Pharmaceuticals, Inc.Similar federal contract value in Biotech · $5.5M in contracts
- Inhalon Biopharma, Inc.Similar federal contract value in Biotech · $5.4M in contracts
- CELL MICROSYSTEMS INCSimilar federal contract value in Biotech · $5.1M in contracts
- AUTONOMOUS THERAPEUTICS INCSimilar federal contract value in Biotech · $4.9M in contracts
- QRONO, INCSimilar federal contract value in Biotech · $4.9M in contracts
- SIGMOVIR BIOSYSTEMS, INC.Similar federal contract value in Biotech · $4.9M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .